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Abstract
Background: Adiponectin is a key mediator of the metabolic syndrome that is caused by visceral
fat accumulation. Adiponectin and its receptors are known to be expressed in osteoblasts, but their
actions with regard to bone metabolism are still unclear. In this study, we investigated the effects
of adiponectin on the proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1
cells.
Results: Adiponectin receptor type 1 (AdipoR1) mRNA was detected in the cells by RT-PCR. The
adenosine monophosphate-activated protein kinase (AMP kinase) was phosphorylated by both
adiponectin and a pharmacological AMP kinase activator, 5-amino-imidazole-4-carboxamide-
riboside (AICAR), in the cells. AdipoR1 small interfering RNA (siRNA) transfection potently
knocked down the receptor mRNA, and the effect of this knockdown persisted for as long as 10
days after the transfection. The transfected cells showed decreased expressions of type I collagen
and osteocalcin mRNA, as determined by real-time PCR, and reduced ALP activity and
mineralization, as determined by von Kossa and Alizarin red stainings. In contrast, AMP kinase
activation by AICAR (0.01–0.5 mM) in wild-type MC3T3-E1 cells augmented their proliferation,
differentiation, and mineralization. BrdU assay showed that the addition of adiponectin (0.01–1.0
μg/ml) also promoted their proliferation. Osterix, but not Runx-2, appeared to be involved in these
processes because AdipoR1 siRNA transfection and AICAR treatments suppressed and enhanced
osterix mRNA expression, respectively.
Conclusion: Taken together, this study suggests that adiponectin stimulates the proliferation,
differentiation, and mineralization of osteoblasts via the AdipoR1 and AMP kinase signaling
pathways in autocrine and/or paracrine fashions.
Background
Cumulative evidence has shown that there is a positive cor-
relation between bone mineral density (BMD) and fat
mass, suggesting that body fat and bone mass are related to
each other [1-6]. Several studies on adipocyte function have
revealed that not only is adipose tissue an energy-storing
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organ but it also secretes a variety of biologically active mol-
ecules, which are named adipocytokines [7]. Adiponectin is
one of the adipocytokines specifically and highly expressed
in adipose tissue. It is also abundantly present in plasma [8]
and has been proposed to play important roles in the regu-
lation of energy homeostasis and insulin sensitivity [9-11].
Two adiponectin receptor subtypes, adiponectin receptor
type 1 and 2 (AdipoR1 and AdipoR2), have been identified;
these mediate the biological effects of adiponectin [12].
AdipoR1 is abundantly expressed in the muscle, whereas
AdipoR2 is predominantly expressed in the liver [12]. Sev-
eral studies indicate that AdipoR1 and AdipoR2 serve as
receptors for globular and full-length adiponectin, respec-
tively, and that their stimulation by adiponectin results in
increased AMP-activated protein kinase (AMP kinase) and
PPARα ligand activities as well as fatty acid oxidation and
glucose uptake in the liver and skeletal muscle [12-14].
Moreover, the expression levels of AdipoR seem to be very
important for adiponectin sensitivity. Obesity decreases
AdipoR expression levels, thereby reducing adiponectin
sensitivity and enhancing insulin resistance [15]. Genetic
variations in AdipoR have been reported to be linked to a
common genetic predisposition to insulin resistance or
type 2 diabetes mellitus [16].
Recently, it has been demonstrated that adiponectin and
its receptors are also expressed in osteoblasts [17-20], sug-
gesting that adiponectin may carry signals and may have a
function in bone tissue as well. However, there have been
only few studies on the physiological actions of adiponec-
tin on osteoblasts, and thus this issue requires further
clarification.
The present study was undertaken to investigate the
abovementioned issue in osteoblastic MC3T3-E1 cells
using AdipoR inhibition by its small interfering RNA
(siRNA) and AMP kinase activation by its pharmacologi-
cal activator 5-aminoimidazole-4-carboxamide-1-β-D-
ribonucleoside (AICAR) [21,22]. The results showed that
adiponectin promoted the proliferation, differentiation,
and mineralization of MC3T3-E1 cells possibly via the
AdipoR1 and AMP kinase pathways, suggesting that adi-
ponectin might cause osteoblastogenesis via AMP kinase
activation.
Results
Expression of adiponectin receptors and knockdown by 
siRNA transfection
We first investigated AdipoR1 and AdipoR2 expressions in
MC3T3-E1 cells. By using RT-PCR, we confirmed that
AdipoR1 mRNA, but not AdipoR2, was expressed in
MC3T3-E1 cells (Fig. 1A). To elucidate the action of adi-
ponectin through AdipoR1, we performed experiments
using an RNA interference to block the receptor expression.
Real-time PCR revealed that a treatment with 50-nM
siRNA-AdipoR1 blocked the expression of AdipoR1 mRNA
(Fig. 1B), while a treatment with cyclophilin B (CypB)
siRNA blocked the expression of CypB mRNA (Fig. 1C),
showing that the knockdown effect of siRNA-AdipoR1 was
specific. The effect of knockdown by siRNA-AdipoR1 per-
sisted for as long as 10 days after the transfection, when the
expression level was still suppressed by 85.1% in compari-
son to that in the control (Fig. 1D).
Effect of AdipoR1 knockdown on the differentiation and 
mineralization of MC3T3-E1 cells
To examine the effect of AdipoR1 knockdown on
MC3T3-E1 cells, we analyzed the differentiation and
mineralization of the siRNA-transfected cells. The total
RNA was collected 4, 7, and 10 days after the siRNA treat-
ment. Real-time PCR showed reduced collagen-I (Col-I)
and osteocalcin (OCN) mRNA levels by the siRNA-
AdipoR1 treatments (Figs. 2A and 2B, respectively). After
the siRNA-AdipoR1 transfection, the ALP activity was
significantly lower than that of the control on day 14 (p
< 0.001) (Fig. 2C), and both von Kossa and Alizarin red
stainings showed that the mineralization was apparently
inhibited by siRNA-AdipoR1 on day 28 (Fig. 3A). The
quantification of the Alizarin red staining showed that
this inhibition was significant (p < 0.001) (Fig. 3B).
These results suggested that adiponectin promotes the
differentiation and mineralization of MC3T3-E1 cells via
AdipoR1.
Effects of adiponectin and AICAR on the AMP kinase 
signaling pathway in MC3T3-E1 cells
To determine whether or not adiponectin or AICAR, a
pharmacological AMP kinase activator, could phosphor-
ylate AMP kinase, MC3T3-E1 cells were incubated with 3
μg/ml recombinant adiponectin or 0.5–2.0 mM AICAR. A
western blot analysis revealed that both adiponectin and
AICAR were able to phosphorylate AMP kinase (Figs. 4A
and 4B, respectively).
Effect of AMP kinase activation on the differentiation 
and mineralization of MC3T3-E1 cells
Because the results above demonstrated that adiponec-
tin and AICAR activated the AMP kinase signaling path-
way in wild-type MC3T3-E1 cells, we examined whether
or not the activation of this pathway would lead to the
differentiation and mineralization of the cells. AICAR
(0.5 mM) was added after the cells reached confluency,
and the total RNA was collected on days 14, 21, and 28.
Real-time PCR showed that in contrast to the results for
siRNA-AdipoR1, the AICAR treatments increased the
expression levels of Col-I and OCN mRNA (Figs. 5A and
5B, respectively). ALP activities were significantly
greater than those of the control at 0.1 and 0.5 mM con-
centrations of AICAR and in a 14-day culture (p < 0.05)
(Fig. 5C). Moreover, both von Kossa and Alizarin redBMC Cell Biology 2007, 8:51 http://www.biomedcentral.com/1471-2121/8/51
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stainings showed that the mineralization of MC3T3-E1
cells was augmented by 0.01–0.5 mM AICAR on day 28
(Fig. 6A). The quantification of the Alizarin red staining
showed that these augmentations were significant (p <
0.001) (Fig. 6B). Thus, the activation of AMP kinase
seemed to promote the differentiation and mineraliza-
tion of MC3T3-E1 cells.
Effect of AdipoR1 knockdown and AICAR treatments on 
Runx-2 expression in MC3T3-E1 cells
Since Runx-2 (also called cbfa1, PEBP2α A) is an impor-
tant transcription factor that is involved in osteoblastic
differentiation and mineralization [23], we investigated
whether or not adiponectin and AICAR modulate its
expression. There were little or no changes in the Runx-2
mRNA levels, as determined by real-time PCR, or its pro-
tein levels (55-kDa band), as determined by immunoblot-
ting under either siRNA-AdipoR1 transfection (Figs. 7A
and 7B, respectively) or AICAR treatment (Figs. 7C and
7D, respectively).
Effect of AdipoR1 knockdown and AICAR treatments on 
osterix expression in MC3T3-E1 cells
Since osterix (Osx) is also an important transcription fac-
tor that is involved in osteoblastic differentiation and
mineralization, we investigated whether or not adiponec-
tin and AICAR modulate its expression. Real-time PCR
showed that Osx mRNA expressions were suppressed by
siRNA-AdipoR1 transfection (Figs. 8A) and enhanced by
AICAR treatments (Figs. 8B).
Effects of adiponectin and AICAR on the proliferation of 
MC3T3-E1 cells
We found that after 24-h incubation with adiponectin or
AICAR, BrdU incorporation was significantly enhanced in
MC3T3-E1 cells (p < 0.01) (Figs. 9A and 9B, respectively).
These results showed that adiponectin and the AMP
kinase activator stimulated the proliferation of the cells.
Discussion
Recent studies have shown that adiponectin and its
receptors were detected not only in adipocytes but also in
Adiponectin R1 and R2 expression in MC3T3-E1 cells and effects of siRNA-AdipoR1 transfection Figure 1
Adiponectin R1 and R2 expression in MC3T3-E1 cells and effects of siRNA-AdipoR1 transfection. (A) Adiponectin receptor 
expression in MC3T3-E1 cells. Total RNA from the cells was subjected to RT-PCR. HPRT, house keeping gene, and AdipoR1 
were visualized in a 2% agarose gel stained with ethidium bromide. AdipoR1 mRNA but not AdipoR2 was expressed in 
MC3T3-E1 cells, while both of them were expressed in 3T3-L1 cells, which were examined as a positive control. (B) Confirma-
tion of the effect of siRNA-AdipoR1. The siRNA restrained only siAdipoR1, showing that its knock down effect was specific 
(p < 0.001). N; 0.2% BSA, TR; transfection reagent, CypB; transfection of siRNA-Cyclophilin B (CypB), control; transfection of 
non-targeting siRNA. (C) Confirmation of the effect of siRNA-CypB. (D) The durability of siRNA-AdipoR1. Total RNA was 
collected at 4, 7, 10 days after siRNA transfection. The knock down effect of siRNA-AdipoR1 was sustained as long as 10 
days after transfection at the expression level of 14.9% of the control. Results are expressed as the mean ± SEM fold increase 
(n = 5) over control values. * p < 0.05, ** p < 0.01, *** p < 0.001.
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bone-forming cells [17-20]. However, little is known
about the physiological action of adiponectin on osteob-
lasts. In this study, we demonstrated that osteoblastic
MC3T3-E1 cells expressed AdipoR1, but not AdipoR2. We
found that the suppression of AdipoR1 expression by its
siRNA inhibited the differentiation and mineralization of
the cells, and we suggested that adiponectin promoted
these processes through the action of AdipoR1 on the
osteoblasts. We also found that adiponectin activated
AMP kinase in the cells, and that AICAR, a pharmacologi-
cal AMP kinase activator [21,22], promoted the differenti-
ation and mineralization of the cells. Both adiponectin
and AICAR also stimulated the proliferation of the cells.
Taken together, adiponectin seemed to promote the pro-
liferation, differentiation, and mineralization of osteob-
lastic MC3T3-E1 cells possibly via the AdipoR1 and AMP
kinase signaling pathway. Recent studies have also shown
that adiponectin promotes osteoblast proliferation
[17,19] and exerts an enhancing action on human osteob-
last differentiation and mineralization [19]. Although we
did not carry out experiments using the inhibitor or siRNA
of AMP kinase, our results seem to be consistent with
those reported in these studies. Further, we disclosed the
involvement of the AMP kinase signaling pathway in the
stimulatory actions of adiponectin on osteoblasts.
Luo et al. have reported that the adiponectin concentra-
tion in fetal bovine serum (FBS) was approximately 60 μg/
ml, which was about six-fold higher than that in human
serum. They have shown that the addition of FBS into the
medium actually enhances the ALP activity of primary
human osteoblasts; however, the addition of adiponectin-
free FBS does not enhance the activity [19]. Therefore, the
influence of adiponectin, which is present in high concen-
trations in FBS, must be ignored when the differentiation
and mineralization of osteoblasts in long cultures are
examined. In this study, we knocked down the expression
of AdipoR1 by transfecting its siRNA and investigated how
the lack of adiponectin action in the microenvironment of
MC3T3-E1 cells would affect the cell functions. There
seem to be two advantages of using MC3T3-E1 cells as a
model system to study the role of adiponectin signaling
on osteoblast growth and differentiation. First, since the
cells produce adiponectin endogenously [17], there is no
need to add adiponectin to the cultures. Second, since the
present study and a previous one [17] showed that the
cells do not express AdipoR2, data interpretation will not
be complicated by the compensatory effect of AdipoR2
after the siRNA knockdown of AdipoR1. By reducing
AdipoR1 expression through its siRNA transfection, we
were able to demonstrate that endogenously produced
Effects of siRNA-AdipoR1 transfection on the differentiation of MC3T3-E1 cells Figure 2
Effects of siRNA-AdipoR1 transfection on the differentiation of MC3T3-E1 cells. Total RNA was collected at 4, 7, 10 days after 
siRNA-AdipoR1 transfection. Col-I (A) and OCN (B) mRNA expression were decreased by blocking the receptor expression. 
Results are expressed as fold increase over the control values at 4 days. The result was the representative of five different 
experiments. (C) ALP activity of siRNA-AdipoR1-transfected MC3T3-E1 cells. ALP activity was evaluated biochemically. ALP 
activity was significantly decreased compared to the control (*** p < 0.001).
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adiponectin was important in osteoblast proliferation and
differentiation as well as in matrix mineralization.
Shinoda et al. have shown that there were no abnormali-
ties in the bone mass or turnover of either adiponectin-
deficient mice or adiponectin-transgenic mice that overex-
pressed adiponectin in the liver [20]. They have reported
that circulating adiponectin suppresses osteoblastogene-
sis through the endocrine pathway, while local adiponec-
tin stimulates it through the autocrine/paracrine pathway
[20]. Additionally, they have suggested that these contra-
dictory effects of adiponectin might explain no apparent
bone changes in its gene-modified mice. In this study, we
found that the blockage of the AdipoR1 expression by
transfecting its siRNA inhibited the differentiation and
mineralization of MC3T3-E1 cells. Since this siRNA trans-
fection obstructed not only the autocrine/paracrine path-
way of adiponectin but also its endocrine pathway,
cytokine might play an important role in the activation of
osteoblasts in the microenvironment of bone marrow.
Yokota et al. have shown that adiponectin is also found in
bone marrow fat cells [24], and Berner et al. have shown
that the level of adiponectin is higher in diluted bone
marrow fluid than in the serum of rats [17]. These facts
suggest that fat cells as well as bone cells might contribute
to the production and high concentration of adiponectin
found in bone marrow. Because adiponectin receptors are
known to be expressed ubiquitously [12], it is possible
that adiponectin can influence not only osteoblasts but
also other lineages of bone marrow cells. In fact, adi-
ponectin has been shown to exert an inhibitory effect on
B lymphopoiesis and a stimulatory effect on myelopoiesis
in bone marrow [24,25]. Thus, further studies seem to be
necessary to clarify the interplay among osteoblasts and
other cells in the biological actions of adiponectin in the
microenvironment of bone marrow.
Runx-2 has been identified as an important transcription
factor that is involved in osteoblast differentiation and min-
eralization [23]. Hence, it is possible that the stimulatory
actions of adiponectin and AICAR on MC3T3-E1 cells in
this study might be mediated by this transcription factor.
However, neither of these agents affected mRNA or protein
expressions of Runx-2, suggesting that the transcription
factor might be not involved in the stimulatory effects of
Effects of siRNA-AdipoR1 transfection on the mineralization of MC3T3-E1 cells Figure 3
Effects of siRNA-AdipoR1 transfection on the mineralization of MC3T3-E1 cells. Mineralization of MC3T3-E1 was evaluated by 
von Kossa and Alizarin red stainings. (A) Plate view of von Kossa and Alizarin red stainings in cultured MC3T3-E1. (B) Quanti-
fication of Alizarin red staining via extraction with etylpyridinium chloride. The amount of released dye was quantified by 
microplate reader at 550 nm. Mineralizarion was significantly decreased in siRNA-AdipoR1 treatment compared to the control 
(*** p < 0.001). The result was the representative of three different experiments.
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adiponectin on MC3T3-E1 cells. On the other hand, there
remains a possibility that the Runx-2 activity can be altered
by the adiponectin signaling pathway. It has been demon-
strated that Runx-2 was activated by Erk via phosphoryla-
tion [26,27]. Although the Erk activity was reported to be
not altered by adiponectin [19], it is not clear from our cur-
rent experiments whether the adiponectin downstream
effector AMP kinase can phosphorylate Runx-2 either
directly or indirectly. Alternatively, we indicated that Osx
mRNA expression was enhanced by adiponectin and
AICAR. Although Osx is generally regarded as the down-
stream effector of Runx-2, the upregulation of Osx mRNA
has been reported without the alteration of Runx-2 mRNA
levels or in the absence of Runx-2 [28,29], suggesting that
Osx and Runx-2 can be differently regulated and Osx can
modulate osteoblastic function independent of Runx-2.
Moreover, Shinoda et al. have recently shown that adi-
ponectin activates the intracellular signaling of insulin in
bone marrow cells through the phosphorylation of IRS-1
and Akt, the main downstream molecules of insulin [20],
thereby suggesting that insulin/IGF-I signaling pathways
might be alternative candidates for mediating the stimula-
tory effects of adiponectin on osteoblasts.
The biological effects of adiponectin are known to be
mediated through the two adiponectin receptor subtypes
AdipoR1 and R2 [12], which subsequently activate AMP
kinase, PPARα ligand, and mitogen-activated protein
kinase (MAPK), and regulate fatty-acid oxidation and glu-
cose uptake [12]. AMP kinase is a highly conserved heter-
otrimeric signaling kinase responsive to hypoxia, exercise,
and cellular stress, and it is associated in a variety of cellu-
lar responses, including suppression of gluconeogenesis
in the liver, promotion of glucose uptake in skeletal mus-
cle, inhibition of fatty acid and sterol synthesis, increase in
fatty acid oxidation, and inhibition of lipolysis [30-34]. In
contrast, there exists little or no information about the
potential roles of this signaling molecule in bone metab-
olism. In this study, we found that AMP kinase activation
promoted the proliferation, differentiation, and
mineralization of MC3T3-E1 cells. AMP kinase is
known to have the ability to phosphorylate and inactivate
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase,
a key regulatory enzyme in the synthesis of cholesterol
and other isoprenoid compounds [35]. Statins, which
also inactivate HMG-CoA reductase, have been shown to
promote osteoblastogenesis via cellular BMP-2 produc-
tion [36,37]. Thus, further studies are necessary to investi-
gate whether or not the activation of AMP kinase would
inactivate HMG-CoA reductase in MC3T3-E1 cells and
enhance their differentiation and mineralization.
A couple of studies have revealed that there are interplays
between the AMP kinase pathway and the MAPK pathway
in the cellular responses of osteoblasts as well as the islet
cells in the pancreas. Kefas et al. have previously shown
that the prolonged activation of AMP kinase by AICAR
promotes apoptosis of the beta cells in the islets through
a sequential activation of JNK [38,39]. Luo et al. have
reported that the adiponectin-induced proliferative
response of human osteoblasts was mediated by the Adi-
poR/JNK pathway, while the differentiation response was
mediated via the AdipoR/p38 MAPK pathway [19].
Although we found that the stimulatory effects of adi-
ponectin on MC3T3-E1 cells might be mediated by AMP
kinase, these previous results suggest that the involvement
of MAPK or other pathways must also be investigated in
future.
Conclusion
Our results suggest that adiponectin stimulates the prolif-
eration, differentiation, and mineralization of osteoblas-
tic MC3T3-E1 cells via the AdipoR1 and AMP kinase
signaling pathways in autocrine and/or paracrine fashions
in the microenvironment of cultured cells. Our findings
seem to be in accord with previous ones that showed that
adiponectin had a stimulatory action on osteoblasts [17-
20] and they seem to extend this notion by showing the
involvement of the AMP kinase pathway in these
processes.
Effects of recombiant adiponectin and AICAR treatments on  AMP kinase activation in MC3T3-E1 cells Figure 4
Effects of recombiant adiponectin and AICAR treatments on 
AMP kinase activation in MC3T3-E1 cells. MC3T3-E1 cells 
were starved in serum-free medium for 2 h and then stimu-
lated by addition of serum-free medium with 3.0 μg/ml 
recombinant adiponectin or 0.5–2.0 mM AICAR. Whole cell 
lysates were collected after 5 min incubation for Western 
blotting. Immunoprecipitation and immunoblotting were per-
formed as described in MATERIALS AND METHODS. The 
lower panels show the intensity of phosphorylated AMP 
kinase (p-AMPK) that was measured using the NIH Image 
Program and was normalized using the total AMP kinase 
(AMPK) signal. Recombinant adiponectin (A) and AICAR (B) 
activated AMP kinase rapidly. The result was the representa-
tive of three different experiments.BMC Cell Biology 2007, 8:51 http://www.biomedcentral.com/1471-2121/8/51
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Methods
Materials
Cell culture medium and supplements were purchased
from Gibco-BRL (Rockville, MD). Recombinant mouse
globular adiponectin, which is produced in E. coli, and
AICAR were purchased from Peprotech EC (London, UK)
and Sigma-Aldrich (St. Louis, MO), respectively. For West-
ern blot analysis, mouse anti-phosphorylated-AMP kinase
and mouse anti-AMP kinase antibodies were purchased
from Cell Signaling Technology (Beverly, MA), and anti-
Runx-2 antibody was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). A secondary antibody (rabbit
anti-mouse IgG) for immunoblotting was obtained from
Sigma (St. Louis, MO). The enhanced chemiluminescence
(ECL) system for Western blot analysis was purchased
from Amersham (Arlington Heights, IL). All other chemi-
cals were of the highest grade available commercially.
Cell cultures
MC3T3-E1 cells, a clonal osteoblastic cell line isolated
from calvariae of late stage mouse embryo [40], were
kindly provided by Kobe University Graduate School of
Medicine, Japan. 3T3-L1 cells, a clonal preadipocyte cell
line, were purchased from RIKEN CELL BANK (Ibaragi,
Japan). MC3T3-E1 cells were cultured in α-minimum
essential medium (α-MEM). This medium was
supplemented with 10% FBS and 1% penicillin-strepto-
mycin (GIBCO-BRL) in 5% CO2 at 37°C. The medium
was changed twice a week. For mineralization assay,
MC3T3-E1 cells were cultured in α-MEM containing 10%
FBS, 1% penicillin-streptomycin, and 10 mM β-glycero-
phosphate for 3 weeks after reaching confluence.
RNA interference for adiponectin receptor
RNA interference was used to down-regulate the expres-
sion of AdipoR1 in MC3T3-E1 cells. SMARTpool small
interfering RNA (siRNA) and SMARTpool reagents for
AdipoR1, CypB and nonspecific control siRNA duplexes
were designed and synthesized by Customer SMARTpool
siRNA Design from Dharmacon (Lafayette, CO). For gene
knock down experiments, MC3T3-E1 cells were plated in
6 cm dish and cultured for 48 hr in α-MEM containing
10% FBS and antibiotics. Next, after 24 hr incubation in
medium without antibiotics, cells were transfected with
siRNAs (50 nM) using transfection reagent according to
the manufacture's instructions. After another 48 hr of cul-
ture, cells were recultured in another in α-MEM contain-
ing 10% FBS and antibiotics.
Effects of an AICAR treatment on the differentiation of MC3T3-E1 cells Figure 5
Effects of an AICAR treatment on the differentiation of MC3T3-E1 cells. AICAR (0.5 mM), a AMP kinase stimulator, was added 
after the cells reached confluency. Total RNA was collected at 14, 21, 28 days. Col-I (A) and OCN (B) mRNA expression were 
increased by the AICAR treatment. Results were expressed as fold increase over the control values at 14 days. The result was 
the representative of three different experiments. (C) ALP activity of MC3T3-E1 cells by an AICAR treatment. ALP activity was 
evaluated biochemically. ALP activity was increased compared to the control significantly (* p < 0.05, and ** p < 0.01).
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RT-PCR analysis of osteoblastic MC3T3-E1 cells mRNA for 
identification of adiponectin receptors
For investigating the expression of AdipoR mRNA in oste-
oblastic MC3T3-E1 cells, reverse transcription (RT)-
polymerase chain reaction (PCR) was performed. Total
RNA was taken from cultured MC3T3-E1 cells using Trizol
reagent (Invitrogen, San Diego, CA) according to the man-
ufacturer's recommended protocol. Two μg total RNA was
employed for the synthesis of single-stranded cDNA
(cDNA synthesis kit; Invitrogen). For amplification of
AdipoR1 and R2, primers were selected as previously
reported (Table 1) [41]. The PCR condition was 95°C for
15 s, 60°C for 30 s, and 72°C for 1 min for 34 cycles. As
an internal standard, cDNA for the housekeeping gene
hypoxanthine phosphoribosyltransferase (HPRT) was
amplified using specific primers. PCR products were sepa-
rated by electrophoresis on 2% agarose gel and visualized
by ethidium bromide staining with ultraviolet (UV) light
using Electronic UV trans-illuminator (Toyobo CO. Ltd,
Tokyo, Japan).
Real-time PCR quantification of gene expression
SYBR green chemistry was used to perform quantitative
determination for the mRNAs for AdipoR1, collagen I,
osteocalcin, Runx-2, and a house keeping gene, 36B4, fol-
lowing an optimized protocol [42,43]. The design of
sense and antisense oligonucleotide primers was based on
published cDNA sequences using the Primer Express
(version 2.0.0, Applied Biosystems). Primer sequences
were listed in Table 1, and cDNA was synthesized with the 
reverse transcription kit (Invitrogen). Real-time PCR was
performed using 1 μl of cDNA in a 25 μl reaction volume
with ABI PRISM 7000 (PE Applied Biosystems Inc.). The
double-stranded DNA-specific dye SYBR Green I was
incorporated into the PCR buffer provided in the Quant-
iTech SYBR PCR kit (QIAGEN, Valencia, CA) to allow for
quantitative detection of the PCR product. The tempera-
ture profile of the reaction was 95°C for 15 min, 40 cycles
of denaturation at 94°C for 15 sec, and annealing and
extension at 60°C for 1 min. 36B4 was used to normalize
Effects of an AICAR treatment on the mineralization of MC3T3-E1 cells Figure 6
Effects of an AICAR treatment on the mineralization of MC3T3-E1 cells. Mineralization of MC3T3-E1 was evaluated by von 
Kossa and Alizarin red stainings. (A) Plate view of von Kossa and Alizarin red stainings in cultured MC3T3-E1 cells. (B) Quanti-
fication of Alizarin red staining via extraction with etylpyridinium chloride. The amount of released dye was quantified by 
microplate reader at 550 nm. Mineralization was significantly increased in the AICAR treatment compared to the control 
(*** p < 0.001). The result was the representative of three different experiments.
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differences in RNA isolation [44], RNA degradation, and
the efficiencies of the reverse transcription.
Assay of alkaline phosphatase activity
After reaching confluence, cells in 24-well plates were
rinsed three times with PBS, and 600 μl of distilled water
were added to each well and sonicated. The protein assay
was performed with the bicinchoninic acid (BCA) protein
assay reagent (Pierce, Rockford, IL). Alkaline phosphatase
(ALP) activity was assayed by a method modified from
that of Lowry et al. [45]. In brief, the assay mixtures con-
tained 0.1 M 2-amino-2-methyl-1-propanol, 1 mM
MgCl2, 8 mM p-nitrophenyl phosphate disodium, and
cell homogenates. After a 4 min of incubation at 37°C,
the reaction was stopped with 0.1 N NaOH, and the
absorbance was read at 405 nm. A standard curve was
prepared with p-nitrophenol. Each value was normalized
to the protein concentration.
Assay of mineralization
Mineralization of MC3T3-E1 cells was determined in 6-
well or 12-well plates using von Kossa staining or Alizarin
red stainings. The cells were fixed with 95% ethanol and
stained with AgNO3 by the von Kossa method to detect
phosphate deposits in bone nodules [46]. At the same
time, the order plates were fixed with ice-cold 70% etha-
nol and stained with Alizarin red to detect calcification.
For quantification, cells stained with Alizarin red (n ≥ 6)
were destained with ethylpyridium chloride, then the
extracted stain was transferred to a 96-well plate, and the
absorbance at 550 nm was measured using a microplate
reader, as previously described [47].
Effects of siRNA-AdipoR1 transfection or an AICAR treatment on Runx-2 mRNA and protein expressions in MC3T3-E1 cells Figure 7
Effects of siRNA-AdipoR1 transfection or an AICAR treatment on Runx-2 mRNA and protein expressions in MC3T3-E1 cells. 
(A and B) Total RNA was collected at 4, 7, 10 days after siRNA-AdipoR1 transfection, and cell lysate was collected at 7 days 
after transfection. Real-time PCR and immunoprecipitation were performed as described in MATERIALS AND METHODS. 
Neither Runx-2 mRNA (A) nor its protein (B) expressions were changed by blocking the receptor expression. (C and D) 
AICAR (0.5 mM), an AMP kinase stimulator, was added after the cells reached confluency. Total RNA was collected at 14, 21, 
28 days, and cell lysate was collected at 14 days. Neither Runx-2 mRNA (C) nor its protein (D) expressions were changed by 
AICAR. The result was the representative of five different experiments.
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Immunoprecipitation and Immunoblotting
For immunoprecipitation and immunoblotting, MC3T3-
E1 cells were plated in 6 cm dish and cultured as described
above. After 2 hr of serum starvation, cells were then stim-
ulated with 3 μg/ml of recombinant mouse adiponectin,
0.5–2 mM AICAR, or vehicle for 5 min. Cells were rinsed
with ice-cold PBS and scraped on ice into lysis buffer (Cell
Signaling Technology) that contained 20 mM Tris-HCl
(pH 7.5), 50 mM NaCl, 1 mM EGTA, 1 mM Na2EDTA, 1%
Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycero-
phosphate, 1 mM Na3VO4, and 1 μg/ml leupeptin. The
cell lysates were then sonicated for 30 sec. Nuclei and cell
debris were removed by centrifugation (12,000 × g for 10
min), and the resultant total cellular lysate in the
Effects of siRNA-AdipoR1 transfection or AICAR treatments  on Osterix mRNA expression in MC3T3-E1 cells Figure 8
Effects of siRNA-AdipoR1 transfection or AICAR treatments 
on Osterix mRNA expression in MC3T3-E1 cells. Total RNA 
was collected at 4, 7, 10 days after siRNA-AdipoR1 transfec-
tion. Real-time PCR was performed as described in MATERI-
ALS AND METHODS. Osterix mRNA expressions was 
suppressed by blocking the receptor expression (A). AICAR 
(0.5 mM), an AMP kinase stimulator, was added after the 
cells reached confluency. Total RNA was collected at 14, 21, 
28 days. Osterix mRNA expressions was enhanced by 
AICAR (B). The result was the representative of five differ-
ent experiments.
Effects of recombinant adiponectin and AICAR treatments  on BrdU incorporation by MC3T3-E1 cells Figure 9
Effects of recombinant adiponectin and AICAR treatments 
on BrdU incorporation by MC3T3-E1 cells. Cells were 
exposed to 0.01–1.0 μg/ml adiponectin or 0.01–0.5 mM 
AICAR for 24 h. Cell proliferation was determined by meas-
uring the amount of incorporated BrdU. Proliferation was 
significantly promoted by both low dose adiponectin (A) and 
AICAR (B) treatments (p < 0.01). The results were the rep-
resentative of three different experiments.
Table 1: Gene names and its primers.
Gene name                       Primers Accession no.
mAdipoR1     CTTCTACTGCTCCCCACAGC NM_028320
   TCCCAGGAACACTCCTGCTC
mAdipoR2    CCACACAACACAAGAATCCG XM_132831
   CCCTTCTTCTTGGGAGAATGG
mCypB    TCGGAGCGCAATATGAAGGT BC013061
   TTCTTCTTATCGTTGGCCACG
mCol-I    AACCCGAGGTATGCTTGATCT NM_007742
   CCAGTTCTTCATTGCATTGC
mOCN    TGCTTGTGACGAGCTATCAG L24431
   GAGGACAGGGAGGATCAAGT
mRunx-2    AAGTGCGGTGCAAACTTTCT NM_009820
   TCTCGGTGGCTGGTAGTGA
mOsterix    CCCTTCTCAAGCACCAATGG AF184902
   AGGGTGGGTAGTCATTTGCATAG
m36B4    AAGCGCGTCCTGGCATTGTCT NM_007475
   CCGCAGGGGCAGCAGTGGT
HPRT    CAGTCCCAGCGTCGTGATTA J00423
   AGCAAGTCTTTCAGTCCTGTC
Primer pairs used for studying various genes.
m; mouse, AdipoR; adiponectin receptor, CypB; cyclophilin B, Col-I; collagen type I, OCN; osteocalcin, HPRT; hypoxanthine 
phosphoribosyltransferase.
36B4 and HPRT are housekeeping genes.BMC Cell Biology 2007, 8:51 http://www.biomedcentral.com/1471-2121/8/51
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supernatant was used for immunoprecipitation. A part of
the cell lysates was immunoprecipitated with an anti-AMP
kinase antibody or anti-Runx-2 antibody conjugated to
protein G-Sepharose (Sigma-Aldrich) overnight at 4°C.
The cell lysates with the immunoprecipitation that con-
tained an equivalent amount of protein were electro-
phoresed by 10% SDS-PAGE and transferred to
nitrocellulose membrane (BIO-RAD, Hercules, CA).
Immunoblot analysis was performed, as previously
described [42]. The blots were incubated overnight at 4°C
with gentle shaking with a phospho-AMP kinase antibody
or Runx-2 antibody at a 1:200 dilution. The blots were
extensively washed with PBS containing 1% Tween 20
(BIO-RAD) and 0.15% dry milk (washing solution) at
room temperature and were further incubated with a
1:2000 dilution of horseradish peroxidase-coupled rabbit
antimouse IgG in PBS containing 1% Tween 20 for 1 hr at
room temperature. The blots were then washed, and the
signal was visualized by chemiluminescence according to
the manufacturer's protocol. After stripping of phospho-
AMP kinase blots, total AMP kinase immunoreactivity was
determined in the same membrane. National Institutes of
Health (NIH) image software (version 1.62) was used to
quantify the signal intensity.
Proliferation assay
MC3T3-E1 cells (approximately 1,000 cells/well) were
seeded out in 96-well plates and cultured for 24 hr. Then
the cells were washed twice with serum-free medium
before addition of new serum-free medium with or with-
out recombinant mouse adiponectin in the range of 0.01–
1.0 μg/ml, and AICAR in the range of 0.01–0.5 mM. After
2 hr, BrdU (5-bromo-2'-deoxyuridine)-labeling solution
(Amersham) was added and the cells were cultured for an
additional 24 hr. At the end of the pulse, the cells were
washed, fixed, and denatured, and an ELISA utilizing an
anti-BrdU peroxidase-conjugated antibody was used to
measure the amount of incorporated BrdU.
Statistics
Results are expressed as a mean ± SEM. Statistical evalua-
tions for differences between groups were carried out
using one-way analysis of variance (ANOVA) followed by
Fisher's protected least significant difference (PLSD). For
all statistical tests, a value of P < 0.05 was considered to be
a statistically significant difference.
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